



# UCB News

## Disposals of own shares

Brussels (Belgium), 3 December 2021 – 20:00 (CET) – regulated information

### Disposal of own shares

In accordance with article 8:6 of the Royal Decree executing the Belgian Code of Companies and Associations, UCB announces that, following exercises of stock options by members of its personnel, it has disposed of UCB shares OTC in view of deliveries of these shares to the relevant members of the personnel, within the framework of the Long Term Incentive Program of the UCB Group, as follows:

Date of transaction	Time	LTI Plan	Number of disposed UCB shares	Price
26 November 2021	16:46:47	Stock Option Plan 2012	1.000	€ 32,36
26 November 2021	16:53:17	Stock Option Plan 2012	1.000	€ 32,36

In addition to these exercises, on 1 December 2021, in accordance with the vesting rules under its 2018, 2019, 2020 and 2021 LTI plans, UCB SA/NV has delivered for free a total of 5 162 UCB shares OTC to 15 members of the personnel of the Company and its subsidiaries. The highest independent bid price on Euronext Brussels on 1 December 2021 was € 96,70.

This press release is available on UCB SA/NV's website via the following [link](#).

#### Investor Relations

Antje Witte  
Investor Relations, UCB

T +32 2 559 94 14,  
[antje.witte@ucb.com](mailto:antje.witte@ucb.com)

#### Corporate Communications

Laurent Schots  
Media Relations, UCB

T+32.2.559.92.64  
[laurent.schots@ucb.com](mailto:laurent.schots@ucb.com)

#### About UCB

UCB, Brussels, Belgium ([www.ucb.com](http://www.ucb.com)) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 8 400 people in nearly 40 countries, the company generated revenue of € 5.3 billion in 2020. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: [@UCB\\_news](https://twitter.com/UCB_news)